ID: ALA4877951

Max Phase: Preclinical

Molecular Formula: C16H16N2O2

Molecular Weight: 268.32

Molecule Type: Unknown

Associated Items:

Representations

Canonical SMILES:  O=C(Nc1ccccc1O)C1NCCc2ccccc21

Standard InChI:  InChI=1S/C16H16N2O2/c19-14-8-4-3-7-13(14)18-16(20)15-12-6-2-1-5-11(12)9-10-17-15/h1-8,15,17,19H,9-10H2,(H,18,20)

Standard InChI Key:  OOBOWDHUFYTQJA-UHFFFAOYSA-N

Associated Targets(Human)

NUGC-3 976 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 268.32Molecular Weight (Monoisotopic): 268.1212AlogP: 2.22#Rotatable Bonds: 2
Polar Surface Area: 61.36Molecular Species: NEUTRALHBA: 3HBD: 3
#RO5 Violations: 0HBA (Lipinski): 4HBD (Lipinski): 3#RO5 Violations (Lipinski): 0
CX Acidic pKa: 8.80CX Basic pKa: 7.51CX LogP: 2.20CX LogD: 2.00
Aromatic Rings: 2Heavy Atoms: 20QED Weighted: 0.73Np Likeness Score: -0.30

References

1. Sim S, Lee S, Ko S, Phuong Bui B, Linh Nguyen P, Cho J, Lee K, Kang JS, Jung JK, Lee H..  (2021)  Design, synthesis, and biological evaluation of potent 1,2,3,4-tetrahydroisoquinoline derivatives as anticancer agents targeting NF-κB signaling pathway.,  46  [PMID:34500188] [10.1016/j.bmc.2021.116371]

Source